

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

07 Jul 2026

### Randomize clinical trial on determining the effect of Erythromycin on the establishment of feeding in infants under 32 weeks gestation

#### Protocol summary

##### Summary

**Objectives:**To determine the effect of erythromycin on the establishment of feeding in infants under 32 weeks gestation. **Design:**randomized, double-blind, clinical trial; **Study population:** 40 preterm infants under 32 weeks gestation hospitalized in the neonatal intensive care unit with a diagnosis of dietary intolerance randomly divided into two groups; **Study type:** one center; **Study phase:** Phase II. **Setting and conduct:** The first group (n=20) that Erythromycin ethyl succinate oral (10 mg per kg every six hours to two days, followed by 4 mg per kg every six hours to 5 days) and group II (n=20) treated with normal saline will receive the same dose and instructions. The duration of treatment for both groups will be equivalent to one week. **Participants:** Inclusion criteria : Infants less than 32 weeks gestational age or weighting less than 1800 g and the minimum age is 5 days after birth and are clinically stable economical state (normal blood pressure Episodes of bradycardia and hypoxemia not) feeding intolerance for less than 75 milli liters per kilogram per day 14 days remain gay or gastric material by more than 50% of 3 hours, which occurred at least two times during the 24 hour period or more than 30% of gastric residues 3 hours ago happened at least three times. **Exclusion criteria :** lethal congenital malformations congenital or chromosomal disorders, cyanotic heart disease, diseases of the gastrointestinal tract obstruction (mal rotation, atresia and Omphalocele, etc.), gastrointestinal surgeries in 14 days ago, NEC suspected or confirmed in the last 7 days, definite or clinical sepsis, metabolic disorders or electrolytic , and treatment with any of the following medications at the onset of feeding intolerance fentanyl , indomethacin , pancuronium. **Interventions :** The use of erythromycin ethylene succinate in the study group. **Main outcome:** Infant can tolerate 150 milliliter per kilogram in at least 24 hours in one day; side effects of treatment include diarrhea, vomiting, pyloric stenosis and evidence of necrotizing enterocolitis; the length of stay in ICU and hospital.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT2015121925591N1**  
Registration date: **2016-06-12, 1395/03/23**  
Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2016-06-12, 1395/03/23

##### Registrant information

##### Name

Maryam Saboute

##### Name of organization / entity

Akbar abadi Hospital

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 5563 2277

##### Email address

saboute.m@iums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Iran University of Medical Sciences Research Center

##### Expected recruitment start date

2015-08-23, 1394/06/01

##### Expected recruitment end date

2016-02-20, 1394/12/01

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

Randomize clinical trial on determining the effect of Erythromycin on the establishment of feeding in infants under 32 weeks gestation

## Public title

Influence of Erythromycin ethyl succinate oral on establishment of feeding in preterm infants

## Purpose

Treatment

## Inclusion/Exclusion criteria

Inclusion criteria: Infants less than 32 weeks gestational age or weighting less than 1800 g with minimum age of 5 days and clinically stable (Normal blood pressure, not having episodes of bradycardia and hypoxemia); Feeding intolerance for less than 75 milliliters per kilogram per day in 14 days; material remaining in the stomach for more than 50% in 3 hours before, which occurred at least two times during the 24 hours; Vomiting more than 30% of gastric residues in 3 hours that happened at least three times Exclusion criteria: Lethal congenital malformations congenital or chromosomal disorders; Cyanotic heart disease; Diseases of the gastrointestinal tract obstruction (Mal rotation, Atresia and Omphalocele, etc.); Gastrointestinal surgeries in 14 days ago; NEC suspected or confirmed in the last 7 days; Definite or clinical sepsis; Metabolic disorders or electrolytic; Treatment with any of the following medications at the onset of feeding intolerance (Fentanyl , Indomethacin, Pancuronium)

## Age

No age limit

## Gender

Both

## Phase

2

## Groups that have been masked

No information

## Sample size

Target sample size: 40

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Double blinded

## Blinding description

## Placebo

Used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

Name of ethics committee

Ethics Committee of Iran University of Medical Sciences, School Medicine

#### Street address

Iran University of Medical Sciences , Hemmat high way , Tehran , Iran

#### City

Tehran

#### Postal code

#### Approval date

2015-11-09, 1394/08/18

#### Ethics committee reference number

IR.IUMS.REC.1394-22688

## Health conditions studied

### 1

#### Description of health condition studied

Premature infants

#### ICD-10 code

P78.9

#### ICD-10 code description

Perinatal digestive system disorder, unspecified

## Primary outcomes

### 1

#### Description

Feeding tolerance of preterm infants

#### Timepoint

5 days after birth less than 32 weeks, less than 1800 gr

#### Method of measurement

Weight

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Erythromycin Ethyl Succinate oral (10 mg per kg every six hours to two days, followed by 4 mg per kg every six hours to 5 days)

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Normal saline (placebo) (10 mg per kg every six hours to two days, followed by 4 mg per kg every six hours to 5 days)

#### Category

Placebo

## Recruitment centers

1

**Recruitment center**

**Name of recruitment center**

Ali Asghar Children Hospital,

**Full name of responsible person**

Dr.Maryam Saboute

**Street address**

Ali Asghar Children Hospital, Vahid Dastgerdi St.,  
Shariati Ave

**City**

Tehran

**Sponsors / Funding sources**

1

**Sponsor**

**Name of organization / entity**

Iran University of Medical Sciences Research Center

**Full name of responsible person**

Dr. Seyed Ali Javad Mousavi

**Street address**

3rd floor, Setad building, in front of Milad Hospital,  
Hemat

**City**

Tehran

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Iran University of Medical Sciences Research Center

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

*empty*

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Ali Asghar Children Hospital

**Full name of responsible person**

Maryam Saboute

**Position**

Assistant professor, Neonatologist

**Other areas of specialty/work**

**Street address**

Ali Asghar Children Hospital, Vahid Dastgerdi  
St.,Shariati Ave

**City**

Tehran

**Postal code**

**Phone**

+98 21 5563 2277

**Fax**

**Email**

saboutem@yahoo.com

**Web page address**

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Ali Asghar Children Hospital

**Full name of responsible person**

Maryam Saboute

**Position**

Assistant Professor

**Other areas of specialty/work**

**Street address**

Ali Asghar Children Hospital, Vahid Dastgerdi  
St.,Shariati Ave

**City**

Tehran

**Postal code**

**Phone**

+98 21 5563 2277

**Fax**

**Email**

saboutem@yahoo.com

**Web page address**

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Ali Asghar Children Hospital

**Full name of responsible person**

Dr.Maryam Saboute

**Position**

Assistant Professor, Neonatologist

**Other areas of specialty/work**

**Street address**

Ali Asghar Children Hospital, Vahid Dastgerdi St.,  
Shariati Ave

**City**

Tehran

**Postal code**

**Phone**

+98 21 5563 2277

**Fax**

**Email**

saboutem@yahoo.com

**Web page address**

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*